MAPT and Alzheimer disease: The potential use of biomarkers in precision medicine is exciting, and caspase-cleaved tau in CSF may add the missing piece to track AD pathology in vivo. CSF D13 caspase-6-cleaved tau is the appealing biofluid biomarker to differentiate AD from 4R-tauopathies.